
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5122624/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. Journal of Pathology, 2022, 256, 108-118.	4.5	12
2	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	1.6	22
3	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology, 2022, , .	4.5	3
4	OUP accepted manuscript. Nucleic Acids Research, 2021, 49, 11005-11021.	14.5	14
5	Identification of deregulation mechanisms specific to cancer subtypes. Journal of Bioinformatics and Computational Biology, 2021, 19, 2140003.	0.8	2
6	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers, 2021, 13, 673.	3.7	9
7	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer, 2021, 148, 181-189.	2.8	70
8	Triple extraction method enables high quality mass spectrometryâ€based proteomics and phosphoâ€proteomics for eventual multiâ€omics integration studies. Proteomics, 2021, 21, 2000303.	2.2	2
9	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nature Communications, 2021, 12, 5578.	12.8	45
10	Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. Cancers, 2021, 13, 87.	3.7	10
11	Highly Sensitive Detection Method of Retinoblastoma Genetic Predisposition and Biomarkers. Journal of Molecular Diagnostics, 2021, 23, 1714-1721.	2.8	12
12	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	1.9	741
13	Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9–13. European Urology, 2020, 77, e26-e27.	1.9	3
14	Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. Cancers, 2020, 12, 2714.	3.7	27
15	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Medicine, 2020, 12, 85.	8.2	39
16	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	1.9	57
17	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. JAMA Ophthalmology, 2020, 138, 569.	2.5	17
18	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemporary Clinical Trials Communications, 2020, 17, 100536.	1.1	13

#	Article	IF	CITATIONS
19	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology, 2020, 77, 436-438.	1.9	1
20	Independent Component Analysis for Unraveling the Complexity of Cancer Omics Datasets. International Journal of Molecular Sciences, 2019, 20, 4414.	4.1	62
21	PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	1.8	10
22	Role of a Kinesin Motor in Cancer Cell Mechanics. Nano Letters, 2019, 19, 7691-7702.	9.1	26
23	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	12.4	67
24	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncolmmunology, 2019, 8, e1581556.	4.6	68
25	APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. European Urology, 2019, 76, 9-13.	1.9	34
26	Assessing reproducibility of matrix factorization methods in independent transcriptomes. Bioinformatics, 2019, 35, 4307-4313.	4.1	23
27	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. British Journal of Cancer, 2019, 120, 555-564.	6.4	23
28	Recurrent activating mutations of PPAR \hat{I}^3 associated with luminal bladder tumors. Nature Communications, 2019, 10, 253.	12.8	44
29	An <scp>FGFR</scp> 3/ <scp>MYC</scp> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Molecular Medicine, 2018, 10, .	6.9	54
30	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 5510-5530.	3.0	11
31	Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. Experimental Cell Research, 2018, 369, 284-294.	2.6	12
32	Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine. Journal of Proteome Research, 2017, 16, 1617-1631.	3.7	25
33	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. BMC Cancer, 2017, 17, 636.	2.6	18
34	SegCorr a statistical procedure for the detection of genomic regions of correlated expression. BMC Bioinformatics, 2017, 18, 333.	2.6	5
35	A prospective multicenter study on bladder cancer: the COBLAnCE cohort. BMC Cancer, 2016, 16, 837.	2.6	11
36	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. Bladder Cancer, 2016, 2, 37-47.	0.4	184

#	Article	IF	CITATIONS
37	A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1. PLoS Genetics, 2016, 12, e1005888.	3.5	29
38	PRC2-independent chromatin compaction and transcriptional repression in cancer. Oncogene, 2015, 34, 741-751.	5.9	10
39	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. Molecular and Cellular Oncology, 2015, 2, e999507.	0.7	1
40	Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 2015, 51, 45-54.	2.8	131
41	C <scp>o</scp> R <scp>eg</scp> N <scp>et</scp> : reconstruction and integrated analysis of co-regulatory networks. Bioinformatics, 2015, 31, 3066-3068.	4.1	46
42	A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. Cancer Research, 2015, 75, 4042-4052.	0.9	96
43	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	6.4	181
44	P <scp>epper</scp> : cytoscape app for protein complex expansion using protein–protein interaction networks. Bioinformatics, 2014, 30, 3419-3420.	4.1	7
45	A siRNA screen identifies RAD21 , EIF3H , CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis, 2014, 35, 670-682.	2.8	44
46	Prediction of recurrence of non muscleâ€invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. Proteomics, 2014, 14, 1333-1342.	2.2	17
47	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	12.4	304
48	PI3K/AKT pathway activation in bladder carcinogenesis. International Journal of Cancer, 2014, 134, 1776-1784.	5.1	74
49	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	1.5	33
50	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human Molecular Genetics, 2014, 23, 5545-5557.	2.9	46
51	Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2013, 61, 2-25.	5.5	29
52	PPAPDC1B and WHSC1L1 Are Common Drivers of the 8p11-12 Amplicon, Not Only in Breast Tumors But Also in Pancreatic Adenocarcinomas and Lung Tumors. American Journal of Pathology, 2013, 183, 1634-1644.	3.8	32
53	New aminopyrimidine derivatives as inhibitors of the TAM family. European Journal of Medicinal Chemistry, 2013, 70, 789-801.	5.5	11
54	HMCan: a method for detecting chromatin modifications in cancer samples using ChIP-seq data. Bioinformatics, 2013, 29, 2979-2986.	4.1	39

#	Article	IF	CITATIONS
55	Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision. PLoS Computational Biology, 2013, 9, e1003286.	3.2	167
56	An essential role for decorin in bladder cancer invasiveness. EMBO Molecular Medicine, 2013, 5, 1835-1851.	6.9	45
57	Network Transformation of Gene Expression for Feature Extraction. , 2012, , .		3
58	Deregulation of Rab and Rab Effector Genes in Bladder Cancer. PLoS ONE, 2012, 7, e39469.	2.5	95
59	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. PLoS ONE, 2012, 7, e48993.	2.5	47
60	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> â€mutated urothelial bladder carcinoma. Journal of Pathology, 2012, 227, 315-324.	4.5	90
61	Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. International Journal of Cancer, 2012, 130, 1367-1377.	5.1	22
62	A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. Journal of the National Cancer Institute, 2011, 103, 47-60.	6.3	66
63	Milk fat globule—epidermal growth factor—factor VIII (MFGE8)/lactadherin promotes bladder tumor development. Oncogene, 2011, 30, 642-653.	5.9	49
64	Gene List significance at-a-glance with GeneValorization. Bioinformatics, 2011, 27, 1187-1189.	4.1	14
65	Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer. European Urology, 2010, 58, 433-441.	1.9	159
66	A prognostic DNA signature for T1T2 nodeâ€negative breast cancer patients. Genes Chromosomes and Cancer, 2010, 49, 1125-1134.	2.8	64
67	Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Molecular Carcinogenesis, 2010, 49, 25-31.	2.7	4
68	Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. Journal of Pathology, 2010, 221, 320-330.	4.5	85
69	Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. Journal of Medical Genetics, 2010, 47, 859-862.	3.2	57
70	Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Annals of Oncology, 2010, 21, 815-819.	1.2	176
71	Quantitative Analysis of Protein Complex Constituents and Their Phosphorylation States on a LTQ-Orbitrap Instrument. Journal of Proteome Research, 2010, 9, 5118-5132.	3.7	26
72	Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors. Organic and Biomolecular Chemistry, 2010, 8, 2164.	2.8	53

#	Article	IF	CITATIONS
73	Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 180-188.	1.6	34
74	Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biology, 2010, 11, R76.	9.6	44
75	8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis. PLoS ONE, 2009, 4, e7239.	2.5	79
76	Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal) Tj ETQq0 (Journal of Gastroenterology, 2008, 103, 2825-2835.	0 rgBT /C 0.4	overlock 10 Tr 118
77	A comprehensive modular map of molecular interactions in RB/E2F pathway. Molecular Systems Biology, 2008, 4, 173.	7.2	113
78	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. Cancer Research, 2008, 68, 7165-7175.	0.9	83
79	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast. Clinical Cancer Research, 2008, 14, 1956-1965.	7.0	148
80	LICORN: learning cooperative regulation networks from gene expression data. Bioinformatics, 2007, 23, 2407-2414.	4.1	40
81	Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas. International Journal of Cancer, 2007, 120, 2058-2059.	5.1	12
82	Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer, 2007, 7, 58.	2.6	17
83	Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. Clinical Cancer Research, 2007, 13, 3545-3551.	7.0	189
84	Regional copy number–independent deregulation of transcription in cancer. Nature Genetics, 2006, 38, 1386-1396.	21.4	198
85	MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene, 2006, 25, 5985-5993.	5.9	115
86	Spatial normalization of array-CGH data. BMC Bioinformatics, 2006, 7, 264.	2.6	71
87	VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics, 2006, 22, 2066-2073.	4.1	106
88	Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics, 2006, 22, 849-856.	4.1	79
89	Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 2006, 27, 740-747.	2.8	128
90	Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation. Clinical Cancer Research, 2006, 12, 2937-2943.	7.0	15

#	Article	IF	CITATIONS
91	Sensitive Allele-Specific PCR Assay Able to Detect FGFR3 Mutations in Tumors and Urine from Patients with Urothelial Cell Carcinoma of the Bladder. Clinical Chemistry, 2005, 51, 1555-1557.	3.2	11
92	Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene, 2005, 24, 7094-7104.	5.9	122
93	Absence ofFGFR3mutations in urinary bladder tumours of rats and mice treated withN-butyl-N-(-4-hydroxybutyl)nitrosamine. Molecular Carcinogenesis, 2005, 42, 142-149.	2.7	4
94	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Human Molecular Genetics, 2005, 14, 1153-1160.	2.9	175
95	Identifying genes from up-down properties of microarray expression series. Bioinformatics, 2005, 21, 3859-3864.	4.1	22
96	Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas. Cancer Research, 2005, 65, 1376-1383.	0.9	62
97	Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Molecular Cancer, 2005, 4, 15.	19.2	61
98	Local Pattern Discovery in Array-CGH Data. Lecture Notes in Computer Science, 2005, , 135-152.	1.3	1
99	Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis, 2004, 26, 177-184.	2.8	68
100	Selecting biomedical data sources according to user preferences. Bioinformatics, 2004, 20, i86-i93.	4.1	18
101	Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene, 2004, 23, 9201-9211.	5.9	43
102	Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. British Journal of Cancer, 2004, 90, 1230-1234.	6.4	25
103	Growth, Differentiation and Senescence of Normal Human Urothelium in an Organ-Like Culture. European Urology, 2004, 45, 799-805.	1.9	29
104	Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. Analytical Biochemistry, 2004, 328, 101-108.	2.4	80
105	Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics, 2004, 20, 3413-3422.	4.1	465
106	Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status*1. Human Pathology, 2004, 35, 817-824.	2.0	26
107	Epidermal Growth Factor Receptor Regulates Normal Urothelial Regeneration. Laboratory Investigation, 2003, 83, 1333-1341.	3.7	33
108	Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 1912-1921.	1.6	294

#	Article	IF	CITATIONS
109	Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clinical Cancer Research, 2003, 9, 257-63.	7.0	62
110	FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Research, 2003, 63, 8108-12.	0.9	196
111	Bayesian Hierarchical Model for Identifying Changes in Gene Expression from Microarray Experiments. Journal of Computational Biology, 2002, 9, 671-683.	1.6	85
112	Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. European Journal of Human Genetics, 2002, 10, 819-824.	2.8	138
113	Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors. American Journal of Pathology, 2001, 158, 1955-1959.	3.8	427
114	Le récepteur de type 3 des FGF (FGFR3) : de la chondrodysplasie… au cancer de la vessie. Medecine/Sciences, 2001, 17, 1189-1191.	0.2	0
115	Characterization of a new brain-specific isoform of the EWS oncoprotein. FEBS Journal, 2001, 268, 3483-3489.	0.2	17
116	No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene, 2001, 20, 5059-5061.	5.9	38
117	p15 INK4b in bladder carcinomas: decreased expression in superficial tumours. British Journal of Cancer, 2001, 85, 1515-1521.	6.4	23
118	The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Research, 2001, 61, 1265-8.	0.9	245
119	Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. British Journal of Cancer, 2000, 83, 209-214.	6.4	69
120	Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis, 2000, 21, 2211-2218.	2.8	56
121	Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene, 1999, 18, 5722-5726.	5.9	26
122	Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene, 1999, 18, 7234-7243.	5.9	125
123	Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. Journal of Steroid Biochemistry and Molecular Biology, 1999, 68, 189-195.	2.5	122
124	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics, 1999, 23, 18-20.	21.4	637
125	Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer*1. Human Pathology, 1998, 29, 1005-1012.	2.0	57
126	Somatic instability of the CTG repeat in mice transgenic for the myotonic dystrophy region is age dependent but not correlated to the relative intertissue transcription levels and proliferative capacities. Human Molecular Genetics, 1998, 7, 1285-1291.	2.9	70

#	Article	IF	CITATIONS
127	Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene, 1997, 14, 323-330.	5.9	80
128	Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 1997, 14, 3059-3066.	5.9	106
129	Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice. Nature Genetics, 1997, 15, 190-192.	21.4	117
130	Functions of fibroblast and transforming growth factors in primary organoid-like cultures of normal human urothelium. Laboratory Investigation, 1996, 75, 147-56.	3.7	8
131	Expression ofmage genes in transitional-cell carcinomas of the urinary bladder. International Journal of Cancer, 1995, 64, 60-64.	5.1	132
132	Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells Molecular Endocrinology, 1994, 8, 929-938.	3.7	91
133	Purification of an acidic phospholipase A2 from Bothrops lanceolatus (fer de lance) venom: Molecular and enzymatic properties. Toxicon, 1994, 32, 1069-1081.	1.6	28
134	Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action. FEBS Journal, 1993, 214, 491-496.	0.2	81
135	Pancreatic beta cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines Molecular and Cellular Biology, 1993, 13, 4223-4232.	2.3	100
136	Pancreatic Î ² Cells Cultured from Individual Preneoplastic Foci in a Multistage Tumorigenesis Pathway: a Potentially General Technique for Isolating Physiologically Representative Cell Lines. Molecular and Cellular Biology, 1993, 13, 4223-4232.	2.3	33
137	Crotoxin, a phospholipase A2 neurotoxin from snake venom, interacts with epithelial mammary cells, is internalized and induces secretion. Molecular and Cellular Endocrinology, 1992, 84, 155.	3.2	1
138	Crotoxin, a phospholipase A2 neurotoxin from snake venom, interacts with epithelial mammary cells, is internalized and induces secretion. Molecular and Cellular Endocrinology, 1991, 82, 41-50.	3.2	18
139	Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell, 1991, 66, 1095-1104.	28.9	506
140	A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. Analytical Biochemistry, 1989, 177, 103-109.	2.4	246
141	Binding of Crotoxin, a Presynaptic Phospholipase A2Neurotoxin, to Negatively Charged Phospholipid Vesicles. Journal of Neurochemistry, 1989, 53, 1252-1260.	3.9	25
142	Binding of divalent and trivalent cations with crotoxin and with its phospholipase and its non-catalytic subunits: effects on enzymatic activity and on the interaction of phospholipase component with phospholipids. Lipids and Lipid Metabolism, 1989, 1006, 183-192.	2.6	11
143	Neutralization of lethal potency and inhibition of enzymatic activity of a phospholipase A2 neurotoxin, crotxin, by non-precipitating antibodies (Fab). FEBS Letters, 1989, 244, 167-173.	2.8	27
144	Site-specific .epsilonamino monoacylation of pancreatic phospholipase A2. 2. Transformation of soluble phospholipase A2 into a highly penetrating "membrane-bound" form. Biochemistry, 1988, 27, 1688-1694.	2.5	44

#	Article	IF	CITATIONS
145	Determination of phospholipase A2 activity by a colorimetric assay using a pH indicator. Toxicon, 1987, 25, 1181-1188.	1.6	158
146	The interaction between the presynaptic phospholipase neurotoxins beta-bungarotoxin and crotoxin and mixed detergent-phosphatidylcholine micelles. A comparison with non-neurotoxic snake venom phospholipases A2 Journal of Biological Chemistry, 1987, 262, 8966-8974.	3.4	35
147	The interaction between the presynaptic phospholipase neurotoxins beta-bungarotoxin and crotoxin and mixed detergent-phosphatidylcholine micelles. A comparison with non-neurotoxic snake venom phospholipases A2. Journal of Biological Chemistry, 1987, 262, 8966-74.	3.4	28
148	Identification of Deregulated Transcription Factors Involved in Specific Bladder Cancer Subtypes. , 0, ,		1